PULSE the living trend engine
↑ Rising Business

Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports

Eli Lilly moves close to a $2.8 billion acquisition of psychedelic pioneer AtaiBeckley, sparking a sharp rally in ATAI shares.

6sources
7articles
9velocity
+228%since first seen
1h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Eli Lilly is reported to be nearing a deal to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion, according to Bloomberg and Reuters. Coverage highlights a steep jump in ATAI stock, with shares soaring 66% on Seeking Alpha and 50% on Barron's after the buyout talks surfaced.

Analysts note a potential 105% takeover premium and expectations that the stock could return to four‑year highs, as cited by Yahoo Finance and CNBC. Observers will watch for an official confirmation of the transaction and any regulatory filings, while monitoring further price movement in ATAI shares.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 29m ago.

Quick answers

What purchase price is being discussed for the AtaiBeckley deal?

The reported price for the acquisition is $2.8 billion.

How have AtaiBeckley’s shares responded to the buyout talks?

Shares rose 66% on Seeking Alpha and 50% on Barron's after the reports emerged.

What premium are investors anticipating?

Venture‑capital sources suggest the offer could represent up to a 105% premium over current market levels.

Coverage (7)

Topics

Eli Lilly AtaiBeckley psychedelics biotech M&A

Related trends